Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases

Introduction: Basal cell carcinoma (BCC) is the most prevalent skin cancer worldwide. The most frequently used treatment for BCC is surgical resection. Lately, there are other options for nonsurgical BCC such as hedgehog pathways inhibitors, which is indicated in patients whose cancer is locally adv...

Full description

Autores:
Castillo Molina, David
Fierro Lozada, Jesus Daniel
García C., Ana María
Molano Pérez, Manuela Alejandra
Cantillo Avilez, Melissa
Guerrero Roncancio, Laura
Muñoz-Ordoñez, Sara
Campo Slebi, Isabella
ALVIS-ZAKZUK, NELSON J.
Castillo Saavedra, David E.
Martinez Zuñiga, Diego M.
Alvis Zakzuk, Nelson J.
Tipo de recurso:
Article of journal
Fecha de publicación:
2021
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/9307
Acceso en línea:
https://hdl.handle.net/11323/9307
https://doi.org/10.1016/j.jaad.2021.06.541
https://repositorio.cuc.edu.co/
Palabra clave:
Cryotherapy
Vismodegib
Basal cell carcinoma
Rights
openAccess
License
© 2021 Published by Elsevier Inc.
id RCUC2_c3c6262925e30c5da9554267e7059dcd
oai_identifier_str oai:repositorio.cuc.edu.co:11323/9307
network_acronym_str RCUC2
network_name_str REDICUC - Repositorio CUC
repository_id_str
dc.title.eng.fl_str_mv Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases
title Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases
spellingShingle Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases
Cryotherapy
Vismodegib
Basal cell carcinoma
title_short Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases
title_full Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases
title_fullStr Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases
title_full_unstemmed Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases
title_sort Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 cases
dc.creator.fl_str_mv Castillo Molina, David
Fierro Lozada, Jesus Daniel
García C., Ana María
Molano Pérez, Manuela Alejandra
Cantillo Avilez, Melissa
Guerrero Roncancio, Laura
Muñoz-Ordoñez, Sara
Campo Slebi, Isabella
ALVIS-ZAKZUK, NELSON J.
Castillo Saavedra, David E.
Martinez Zuñiga, Diego M.
Alvis Zakzuk, Nelson J.
dc.contributor.author.spa.fl_str_mv Castillo Molina, David
Fierro Lozada, Jesus Daniel
García C., Ana María
Molano Pérez, Manuela Alejandra
Cantillo Avilez, Melissa
Guerrero Roncancio, Laura
Muñoz-Ordoñez, Sara
Campo Slebi, Isabella
ALVIS-ZAKZUK, NELSON J.
Castillo Saavedra, David E.
Martinez Zuñiga, Diego M.
dc.contributor.author.none.fl_str_mv Alvis Zakzuk, Nelson J.
dc.subject.proposal.eng.fl_str_mv Cryotherapy
Vismodegib
Basal cell carcinoma
topic Cryotherapy
Vismodegib
Basal cell carcinoma
description Introduction: Basal cell carcinoma (BCC) is the most prevalent skin cancer worldwide. The most frequently used treatment for BCC is surgical resection. Lately, there are other options for nonsurgical BCC such as hedgehog pathways inhibitors, which is indicated in patients whose cancer is locally advanced and unresectable. We described the response of patients treated with vismodegib and cryotherapy as adjuvant management. Materials and methods: We conducted an observational retrospective study in a dermatologic center in Bogota, Colombia. We included patients with BCC diagnosis and were treated with vismodegib and cryotherapy from January 2018 to August 2020. Variables included age, sex, phototype, lesion location, treatment duration, number of cryotherapies, months of follow-up, and histologic subtypes. Variables were analyzed using Microsoft Excel 2016. Results: Of eight patients reviewed, four were female. Median age was 70 years old. Photoype III was the most frequent. Zone H was the most affected location. The mean number of cryotherapy sessions received during vismodegib treatment was 4.75, and the mean duration of treatment with the hedgehog inhibitor was 3.5 months. Patients were followed up for 15.57 months. Of the eight patients, four presented nodular pattern histology, in the rest the mixed subtype predominated. Conclusion: In general, there was a good response to treatment with a notable decrease in the size and control of the lesions. No side effects were described during the follow-up time; however, the patients will continue to be under strict controls.
publishDate 2021
dc.date.issued.none.fl_str_mv 2021-09-01
dc.date.accessioned.none.fl_str_mv 2022-06-24T13:44:49Z
dc.date.available.none.fl_str_mv 2022-06-24T13:44:49Z
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
format http://purl.org/coar/resource_type/c_6501
status_str acceptedVersion
dc.identifier.citation.spa.fl_str_mv David A. Castillo Molina, Jesus D. Fierro Lozada, Ana María García C, Manuela A. Molano Pérez, Melissa Cantillo Avilez, Laura Guerrero-Roncancio, Sara Muñoz-Ordoñez, Isabella Campo Slebi, Nelson José Alvis-Zakzuk, David E. Castillo Saavedra, Diego M. Martinez Zuñiga, 27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: A report of 8 cases, Journal of the American Academy of Dermatology, Volume 85, Issue 3, Supplement, 2021, Page AB131, ISSN 0190-9622, https://doi.org/10.1016/j.jaad.2021.06.541.
dc.identifier.issn.spa.fl_str_mv 0190-9622
dc.identifier.uri.spa.fl_str_mv https://hdl.handle.net/11323/9307
dc.identifier.url.spa.fl_str_mv https://doi.org/10.1016/j.jaad.2021.06.541
dc.identifier.doi.spa.fl_str_mv 10.1016/j.jaad.2021.06.541
dc.identifier.eissn.spa.fl_str_mv 1097-6787
dc.identifier.instname.spa.fl_str_mv Corporación Universidad de la Costa
dc.identifier.reponame.spa.fl_str_mv REDICUC - Repositorio CUC
dc.identifier.repourl.spa.fl_str_mv https://repositorio.cuc.edu.co/
identifier_str_mv David A. Castillo Molina, Jesus D. Fierro Lozada, Ana María García C, Manuela A. Molano Pérez, Melissa Cantillo Avilez, Laura Guerrero-Roncancio, Sara Muñoz-Ordoñez, Isabella Campo Slebi, Nelson José Alvis-Zakzuk, David E. Castillo Saavedra, Diego M. Martinez Zuñiga, 27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: A report of 8 cases, Journal of the American Academy of Dermatology, Volume 85, Issue 3, Supplement, 2021, Page AB131, ISSN 0190-9622, https://doi.org/10.1016/j.jaad.2021.06.541.
0190-9622
10.1016/j.jaad.2021.06.541
1097-6787
Corporación Universidad de la Costa
REDICUC - Repositorio CUC
url https://hdl.handle.net/11323/9307
https://doi.org/10.1016/j.jaad.2021.06.541
https://repositorio.cuc.edu.co/
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofjournal.spa.fl_str_mv Journal of the American Academy of Dermatology
dc.relation.citationissue.spa.fl_str_mv 3
dc.relation.citationvolume.spa.fl_str_mv 85
dc.rights.spa.fl_str_mv © 2021 Published by Elsevier Inc.
Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv © 2021 Published by Elsevier Inc.
Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)
https://creativecommons.org/licenses/by-nc-sa/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.extent.spa.fl_str_mv 1 página
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Mosby Inc.
dc.publisher.place.spa.fl_str_mv United States
institution Corporación Universidad de la Costa
dc.source.url.spa.fl_str_mv https://www.sciencedirect.com/science/article/pii/S0190962221016455?via%3Dihub
bitstream.url.fl_str_mv https://repositorio.cuc.edu.co/bitstreams/53955e25-4c5f-4624-935f-8dab9832dedc/download
https://repositorio.cuc.edu.co/bitstreams/5439741f-4f1d-4c9b-8938-853c3947c3e9/download
https://repositorio.cuc.edu.co/bitstreams/6a2e081b-1745-4b4a-9586-92dff3368e99/download
https://repositorio.cuc.edu.co/bitstreams/8428aa3c-b116-43b8-8fac-b3d13a027389/download
bitstream.checksum.fl_str_mv 550e3522ec17a3d3d54c52a37d12b17d
e30e9215131d99561d40d6b0abbe9bad
472acd6d7e08130ceaf0b9fbcf350780
0f3750738f93bd00c645a6162cde60e7
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio de la Universidad de la Costa CUC
repository.mail.fl_str_mv repdigital@cuc.edu.co
_version_ 1828166908053028864
spelling Castillo Molina, DavidFierro Lozada, Jesus DanielGarcía C., Ana MaríaMolano Pérez, Manuela AlejandraCantillo Avilez, MelissaGuerrero Roncancio, LauraMuñoz-Ordoñez, SaraCampo Slebi, IsabellaALVIS-ZAKZUK, NELSON J.Castillo Saavedra, David E.Martinez Zuñiga, Diego M.Alvis Zakzuk, Nelson J.virtual::251-12022-06-24T13:44:49Z2022-06-24T13:44:49Z2021-09-01David A. Castillo Molina, Jesus D. Fierro Lozada, Ana María García C, Manuela A. Molano Pérez, Melissa Cantillo Avilez, Laura Guerrero-Roncancio, Sara Muñoz-Ordoñez, Isabella Campo Slebi, Nelson José Alvis-Zakzuk, David E. Castillo Saavedra, Diego M. Martinez Zuñiga, 27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: A report of 8 cases, Journal of the American Academy of Dermatology, Volume 85, Issue 3, Supplement, 2021, Page AB131, ISSN 0190-9622, https://doi.org/10.1016/j.jaad.2021.06.541.0190-9622https://hdl.handle.net/11323/9307https://doi.org/10.1016/j.jaad.2021.06.54110.1016/j.jaad.2021.06.5411097-6787Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Introduction: Basal cell carcinoma (BCC) is the most prevalent skin cancer worldwide. The most frequently used treatment for BCC is surgical resection. Lately, there are other options for nonsurgical BCC such as hedgehog pathways inhibitors, which is indicated in patients whose cancer is locally advanced and unresectable. We described the response of patients treated with vismodegib and cryotherapy as adjuvant management. Materials and methods: We conducted an observational retrospective study in a dermatologic center in Bogota, Colombia. We included patients with BCC diagnosis and were treated with vismodegib and cryotherapy from January 2018 to August 2020. Variables included age, sex, phototype, lesion location, treatment duration, number of cryotherapies, months of follow-up, and histologic subtypes. Variables were analyzed using Microsoft Excel 2016. Results: Of eight patients reviewed, four were female. Median age was 70 years old. Photoype III was the most frequent. Zone H was the most affected location. The mean number of cryotherapy sessions received during vismodegib treatment was 4.75, and the mean duration of treatment with the hedgehog inhibitor was 3.5 months. Patients were followed up for 15.57 months. Of the eight patients, four presented nodular pattern histology, in the rest the mixed subtype predominated. Conclusion: In general, there was a good response to treatment with a notable decrease in the size and control of the lesions. No side effects were described during the follow-up time; however, the patients will continue to be under strict controls.1 páginaapplication/pdfengMosby Inc.United States© 2021 Published by Elsevier Inc.Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0)https://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: a report of 8 casesArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/acceptedVersionhttps://www.sciencedirect.com/science/article/pii/S0190962221016455?via%3DihubJournal of the American Academy of Dermatology385CryotherapyVismodegibBasal cell carcinomaPublication969b7cc2-4eeb-48c0-b0b4-eb93f794dd65virtual::251-1969b7cc2-4eeb-48c0-b0b4-eb93f794dd65virtual::251-1https://scholar.google.com.co/citations?user=Paic_C8AAAAJ&hl=esvirtual::251-10000-0001-9382-214Xvirtual::251-1ORIGINAL27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdfapplication/pdf132914https://repositorio.cuc.edu.co/bitstreams/53955e25-4c5f-4624-935f-8dab9832dedc/download550e3522ec17a3d3d54c52a37d12b17dMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-83196https://repositorio.cuc.edu.co/bitstreams/5439741f-4f1d-4c9b-8938-853c3947c3e9/downloade30e9215131d99561d40d6b0abbe9badMD52TEXT27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf.txt27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf.txttext/plain9474https://repositorio.cuc.edu.co/bitstreams/6a2e081b-1745-4b4a-9586-92dff3368e99/download472acd6d7e08130ceaf0b9fbcf350780MD53THUMBNAIL27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf.jpg27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma.pdf.jpgimage/jpeg15982https://repositorio.cuc.edu.co/bitstreams/8428aa3c-b116-43b8-8fac-b3d13a027389/download0f3750738f93bd00c645a6162cde60e7MD5411323/9307oai:repositorio.cuc.edu.co:11323/93072025-02-18 15:56:14.356https://creativecommons.org/licenses/by-nc-sa/4.0/© 2021 Published by Elsevier Inc.open.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.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